Here is a toss out question for this board to chew on and give your opinion if you care to participate.
Based on what is in the public domain or otherwise, how much, if anything, is Abbott likely telling BioCurex management about its progress in developing serum RECAF technology into tests on Abbott's Architect system? Keep in mind the following:
1. BioCurex management has stated that "the licensee (Abbott) sets the timetable."
2. When asked (Erthang interview) how long do you think it will take before we see a RECAF product from Abbott, Dr. Moro responded "I can't tell you. I have an idea, but Abbott has muffled me. I can't say because of the regulations."
3. Any RECAF assay developed by Abbott to run on automated analyzers would likely be patentable by Abbott.
kag
